Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Sep 20;10:4317. doi: 10.1038/s41467-019-11777-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — AAV9 mediated overexpression of circFndc3b improves cardiac function 8 weeks after MI in mice: a AAV9 vector expressing circFndc3b. b, c RT-qPCR analysis of precursor-circFNDC3b (n = 6 mice/group) and endogenous circFndc3b expression (n = 6 mice/group) in AAV9 circFndc3b or AAV9 control treated hearts at 8 weeks post MI. n = 5–7/group. *p < 0.05, ***p < 0.001 vs AAV9 control (two-sided unpaired students t-test); c, d RT-qPCR analysis of linear Fndc3b mRNA expression in AAV9 circFndc3b (n = 5 mice/group) or AAV9 control treated hearts (n = 6 mice/group) at 8 weeks post MI. Not significant (ns) vs AAV9 control (two-sided unpaired students t-test); f–i AAV9 mediated overexpression of circFndc3b (n = 7 mice) improved LV function (% ejection fraction, % fractional shortening, LVID; s and LVID; d measured by echocardiography compared to AAV9 control (n = 6 mice) or saline treatment groups (n = 5 mice). Data are Mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 vs AAV9 control treated hearts. ^#p < 0.05, ^##p < 0.01, ^###p < 0.001 vs saline treated hearts, non-significant between saline and AAV9 control treated hearts (Two-way ANOVA). The round dots represent AAV9 control and square denotes AAV9-circFndc3b

HHS Vulnerability Disclosure